World Hepatitis Day 2025 | Prof. George Lau: Exploring Optimal Strategies for HBV Antiviral Therapy from an Economic Perspective

World Hepatitis Day 2025 | Prof. George Lau: Exploring Optimal Strategies for HBV Antiviral Therapy from an Economic Perspective

2025.12.02
At the 2025 World Hepatitis Day Campaign Conference and the 7th Academic Conference on Clinical Cure of Chronic Hepatitis B, hosted by the China Foundation for Hepatitis Prevention and Control, Professor George Lau, Chairman of Hong Kong’s Humanity Medical Group and Chief Physician at Zhongshan Hospital affiliated with Fudan University, shared insights on the most cost-effective strategies for HBV antiviral therapy from an economic perspective. Hepatology Digest invited Prof. George Lau for an in-depth interview on the current status of hepatitis B prevention and treatment as well as economic evaluation.
APASL 2025 Expert Interview | Prof. George Lau: Dilemmas and Breakthroughs in Clinical Cure of Chronic Hepatitis B and Liver Cancer Prevention

APASL 2025 Expert Interview | Prof. George Lau: Dilemmas and Breakthroughs in Clinical Cure of Chronic Hepatitis B and Liver Cancer Prevention

2025.12.02
At the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025), Professor George Lau, Chairman of Hong Kong Humanity Medical Group and Director of Humanity Medical Clinical Research Center, shared important insights on cuttingedge topics including clinical cure of chronic hepatitis B (CHB) and liver cancer prevention. With the WHO’s 2030 goal to eliminate CHB approaching, China’s CHB prevention and treatment efforts face new opportunities and challenges. In this exclusive interview, drawing on his extensive clinical experience, Professor Lau systematically outlines key breakthroughs and remaining dilemmas in the fields of CHB clinical cure and liver cancer prevention, offering valuable professional perspectives to advance China’s work in CHB and liver cancer control.
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

2025.12.01
In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more work together to design optimal, personalized treatment plans—from diagnosis and strategy development to timing of therapy and long-term follow-up.
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

2025.12.01
With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University Cancer Center delivered a keynote lecture titled “Rational Reflections Amid the Surge of Immunotherapy in RCC.” After the session, Oncology Frontier – Urology Frontier invited Prof. Dong for an in-depth discussion on the evolving role of neoadjuvant therapy, adjuvant immunotherapy, and precision strategies for FH-deficient RCC. 
Professor Alejandro Madrigal: The Path to Breakthrough for the Localization of CAR-T Cell Therapy in Latin America 

Professor Alejandro Madrigal: The Path to Breakthrough for the Localization of CAR-T Cell Therapy in Latin America 

2025.12.01
In the global wave of medical innovation, emerging therapies such as CAR-T cell therapy have brought revolutionary hope for major diseases, including malignancies. However, their widespread adoption and application face significant regional imbalances, with low- and middle-income countries encountering numerous structural barriers in accessing these frontier technologies. From November 13 to 16, 2025, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, Zhejiang. During the conference, Oncology Frontier - Hematology specially invited Professor Alejandro Madrigal from University College London (UCL) to discuss, from an international perspective and using Mexico as a case study, the core challenges Latin America faces in promoting equitable access to medical resources and introducing cutting-edge therapies.